In addition, other groups have demonstrated that survivin inhibition is a common mechanism of apoptosis induced in CML cells by different classes of anticancer agents such as aurora kinase inhibitors, histone deacetylase inhibitors [149], microtubule targeting agents (MTAs), and cyclin-dependent kinase (CDK1) inhibitors [150]. Here, BIRC5 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.